Photo from wikipedia
Apatinib, an oral antiangiogenic drug, exerts potential anti‐tumour effects on platinum‐resistant recurrent ovarian cancer (PROC). This study intended to evaluate the efficacy and safety of apatinib plus paclitaxel compared to… Click to show full abstract
Apatinib, an oral antiangiogenic drug, exerts potential anti‐tumour effects on platinum‐resistant recurrent ovarian cancer (PROC). This study intended to evaluate the efficacy and safety of apatinib plus paclitaxel compared to paclitaxel monotherapy in PROC patients.
Keywords:
recurrent ovarian;
platinum resistant;
ovarian cancer;
apatinib plus;
plus paclitaxel;
resistant recurrent
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!